Cullinan Therapeutics, Inc.
CGEM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $41,968 | $61,030 | $41,459 | $40,492 |
| G&A Expenses | $13,627 | $14,768 | $13,537 | $14,556 |
| SG&A Expenses | $13,627 | $14,768 | $13,537 | $14,556 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $55,595 | $75,798 | $54,996 | $55,048 |
| Operating Income | -$55,595 | -$75,798 | -$54,996 | -$55,048 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,985 | $5,743 | $6,495 | $7,518 |
| Pre-Tax Income | -$50,610 | -$70,055 | -$48,501 | -$47,530 |
| Tax Expense | $0 | $0 | $0 | $117 |
| Net Income | -$50,610 | -$70,055 | -$48,501 | -$47,647 |
| % Margin | – | – | – | – |
| EPS | 0 | -1.19 | -0.82 | -0.81 |
| % Growth | 100% | -45.1% | -1.2% | – |
| EPS Diluted | 0 | -1.19 | -0.82 | -0.81 |
| Weighted Avg Shares Out | 59,015 | 59,015 | 58,905 | 58,580 |
| Weighted Avg Shares Out Dil | 59,015 | 59,015 | 58,905 | 58,580 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,093 | $5,924 | $6,580 | $7,512 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $79 | $77 | $76 | $77 |
| EBITDA | -$50,531 | -$75,721 | -$54,920 | -$54,971 |
| % Margin | – | – | – | – |